

EDWARDS LIFESCIENCES CORPORATION
Unaudited Consolidated Statements of Operations

(in millions, except per share data)	Three Months Ended June 30,		Six Months Ended June 30,	
	2007	2006	2007	2006
Net sales	\$272.6	\$267.3	\$536.7	\$524.0
Cost of goods sold	94.7	95.7	187.9	188.8
Gross profit	177.9	171.6	348.8	335.2
Selling, general and administrative expenses	101.7	97.0	200.3	189.2
Research and development expenses	29.1	28.9	57.9	56.1
Special gains, net	-	(0.7)	-	(24.5)
Interest expense, net	0.4	0.6	0.6	1.5
Other expenses (income), net	(0.1)	0.3	(1.4)	1.0
Income before provision for income taxes	46.8	45.5	91.4	111.9
Provision for income taxes	11.9	9.4	23.3	29.9
Net income	\$34.9	\$36.1	\$68.1	\$82.0
Earnings per share:				
Basic earnings per share	\$0.61	\$0.61	\$1.18	\$1.39
Diluted earnings per share	\$0.57	\$0.58	\$1.11	\$1.30
Weighted average common shares outstanding:				
Basic	57.5	58.8	57.7	59.0
Diluted	63.0	64.2	63.2	64.4

Operating Statistics

As a percentage of net sales:				
Gross profit	65.3%	64.2%	65.0%	64.0%
Selling, general and administrative expenses	37.3%	36.3%	37.3%	36.1%
Research and development expenses	10.7%	10.8%	10.8%	10.7%
Income before provision for income taxes	17.2%	17.0%	17.0%	21.4%
Net income	12.8%	13.5%	12.7%	15.6%
Effective tax rate	25.4%	20.7%	25.5%	26.7%

Computation of Diluted Earnings per Share

Net income	\$34.9	\$36.1	\$68.1	\$82.0
Adjustment for interest expense included in net income	1.0	1.0	2.0	2.0
Adjusted net income	\$35.9	\$37.1	\$70.1	\$84.0
Weighted average common shares outstanding used to calculate diluted earnings per share excluding contingent convertible debt	60.3	61.5	60.5	61.7
Weighted average common shares outstanding for the contingent convertible debt	2.7	2.7	2.7	2.7
Weighted average common shares outstanding used to calculate diluted earnings per share including the contingent convertible debt	63.0	64.2	63.2	64.4
Diluted earnings per share including the contingent convertible debt	\$0.57	\$0.58	\$1.11	\$1.30

Note: Numbers may not foot due to rounding

EDWARDS LIFESCIENCES CORPORATION**Unaudited Balance Sheets**

(in millions)

	<u>June 30, 2007</u>	<u>December 31, 2006</u>
ASSETS		
Current assets		
Cash and cash equivalents	\$164.9	\$182.8
Accounts and other receivables, net	137.4	127.1
Inventories, net	143.5	142.1
Deferred income taxes	25.4	21.8
Prepaid expenses and other current assets	70.0	57.8
Total current assets	<u>541.2</u>	<u>531.6</u>
Property, plant and equipment, net	220.2	213.0
Goodwill	337.7	337.7
Other intangible assets, net	107.5	116.1
Investments in unconsolidated affiliates	25.1	20.2
Deferred income taxes	4.8	14.5
Other assets	15.3	13.7
Total assets	<u><u>\$1,251.8</u></u>	<u><u>\$1,246.8</u></u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities		
Accounts payable and accrued liabilities	\$173.6	\$226.2
Convertible debt	150.0	-
Total current liabilities	<u>323.6</u>	<u>226.2</u>
Long-term debt	57.6	235.9
Other long-term liabilities	63.1	35.3
Stockholders' equity		
Common stock	67.9	67.0
Additional contributed capital	644.0	603.7
Retained earnings (1)	503.7	433.9
Accumulated other comprehensive loss	(8.9)	(15.8)
Common stock in treasury, at cost	(399.2)	(339.4)
Total stockholders' equity	<u>807.5</u>	<u>749.4</u>
Total liabilities and stockholders' equity	<u><u>\$1,251.8</u></u>	<u><u>\$1,246.8</u></u>

(1) Effective January 1, 2007, the Company adopted Financial Accounting Standard Board ("FASB") Interpretation No. 48, "Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statement No. 109" ("FIN 48"). The adoption of FIN 48 increased the January 1, 2007 balance of retained earnings by \$1.7 million.

EDWARDS LIFESCIENCES CORPORATION

Non-GAAP Financial Information

To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses non-GAAP financial measures that exclude certain items, such as in-process research and development expenses, special charges and gains, results of discontinued products, and fluctuations in exchange rates. Management does not consider the excluded items part of day-to-day business or reflective of the core operational activities of the Company as they result from transactions outside the ordinary course of business.

Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. Certain guidance is provided only on a non-GAAP basis that excludes special items and foreign exchange fluctuations due to the inherent difficulty in forecasting such items. By disclosing non-GAAP financial measures, management intends to provide investors with a more meaningful, consistent comparison of the Company's core operating results and trends for the periods presented.

Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, nor superior to, the corresponding measures calculated in accordance with GAAP.

The items described below are excluded from the GAAP financial results in the reconciliations that follow:

Special gains, net - The Company incurred certain special charges and gains in 2006 related to the following:

- 1) *Gain on sale of products: \$4.5 million gain from the sale of a non-strategic business in the second quarter of 2006, and \$5.7 million gain from cash received in the first quarter of 2006 as the final earn-out payment in the prior year's sale of the Japan Perfusion product line to Terumo;*
- 2) *Impairment of assets: \$2.6 million impairment charge in the second quarter of 2006 related to the revaluation of the Company's remaining international perfusion product assets;*
- 3) *Litigation reserve: \$1.2 million charge for litigation reserves in the second quarter of 2006;*
- 4) *Gain on patent settlement: \$20.2 million gain from a patent settlement with Medtronic in the first quarter of 2006;*
- 5) *Realignment expenses: \$2.1 million charge for primarily severance expenses in the first quarter of 2006 resulting from the planned closing of a manufacturing facility.*

Given the magnitude and unusual nature of these special charges and gains relative to the operating results for the periods presented, these items have been excluded from non-GAAP net income.

Provision (Benefit) For Income Taxes - The Company benefited \$3.7 million in the second quarter of 2006 related to the reversal of a valuation allowance, triggered by the gain from the sale of a product line. Given the magnitude and unusual nature of this tax event relative to the period presented, this item has been excluded from non-GAAP net income.

Results of Discontinued Products – The Company has discontinued certain products during the periods presented. As discontinued products do not have a continuing contribution to operations, management believes that excluding such items from the Company's sales growth provides investors with a means of evaluating the Company's on-going operations. In light of the significance of the impact these products had on the sales growth of the Company, the sales results of these products have been detailed in the "Unaudited Reconciliation of Sales by Product Line and Region."

Foreign Exchange - Fluctuation in exchange rates impacts the comparative results and sales growth rates of the Company's underlying business. Management believes that excluding the impact of foreign exchange rate fluctuations from its sales growth provides investors a more meaningful comparison to historical financial results. The impact of foreign exchange rate fluctuations has been detailed in the "Unaudited Reconciliation of Sales by Product Line and Region."

EDWARDS LIFESCIENCES CORPORATION
Reconciliation of GAAP to Non-GAAP Financial Information

(in millions, except per share data)	Three Months Ended June 30,		Six Months Ended June 30,	
	2007	2006	2007	2006
GAAP net income	\$34.9	\$36.1	\$68.1	\$82.0
Reconciling items:				
Special charges (gains), net				
Gain on sale of products	-	(4.5)	-	(10.2)
Impairment of assets	-	2.6	-	2.6
Litigation reserve	-	1.2	-	1.2
Gain on patent settlement	-	-	-	(20.2)
Realignment expenses	-	-	-	2.1
Subtotal special gains, net	-	(0.7)	-	(24.5)
Provision (benefit) for income taxes				
Tax effect on non-GAAP adjustments (1)	-	1.8	-	11.2
Tax benefit from reversal of valuation allowance	-	(3.7)	-	(3.7)
Subtotal provision (benefit) for income taxes, net	-	(1.9)	-	7.5
Non-GAAP net income	\$34.9	\$33.5	\$68.1	\$65.0
Non-GAAP earnings per share:				
Basic non-GAAP earnings per share	\$0.61	\$0.57	\$1.18	\$1.10
Diluted non-GAAP earnings per share (2)	\$0.57	\$0.54	\$1.11	\$1.04
Weighted average shares outstanding:				
Basic	57.5	58.8	57.7	59.0
Diluted	63.0	64.2	63.2	64.4

(1) The tax effect on non-GAAP adjustments is calculated using the relevant tax jurisdiction of the transaction applying the local statutory tax rate.

(2) Diluted non-GAAP earnings per share is calculated by adding back to net income \$1.0 million for the quarter in interest expense related to the convertible debt for the quarter, and \$2.0 million for the six month period, then dividing by the weighted average diluted shares outstanding.

EDWARDS LIFESCIENCES CORPORATION
Unaudited Reconciliation of Sales by Product Line and Region
(in millions)

Sales by Product Line (QTD)					2007 Adjusted		2006 Adjusted			Underlying Growth % *
	2Q 2007	2Q 2006	Change	GAAP Growth Rate	Discontinued Product Line Impact	2Q 2007 Underlying Sales	Discontinued Product Line Impact	FX Impact	2Q 2006 Underlying Sales	
Heart Valve Therapy	\$ 131.3	\$ 127.8	\$ 3.5	2.7%	\$ (2.1)	\$ 129.2	\$ (3.0)	\$ 2.9	\$ 127.7	1.1%
Critical Care	97.4	89.6	7.8	8.7%	-	97.4	-	1.7	91.3	6.7%
Cardiac Surgery Systems	15.2	24.3	(9.1)	(37.4%)	(1.2)	14.0	(10.6)	0.4	14.1	(0.6%)
Vascular	22.3	19.1	3.2	16.8%	-	22.3	(0.7)	0.7	19.1	16.7%
Other Distributed Products	6.4	6.5	(0.1)	(1.5%)	-	6.4	(0.3)	(0.2)	6.0	7.4%
Total Sales	\$ 272.6	\$ 267.3	\$ 5.3	2.0%	\$ (3.3)	\$ 269.3	\$ (14.6)	\$ 5.5	\$ 258.2	4.3%

Sales by Product Line (YTD)					2007 Adjusted		2006 Adjusted			Underlying Growth % *
	YTD 2Q 2007	YTD 2Q 2006	Change	GAAP Growth Rate	Discontinued Product Line Impact	YTD 2007 Underlying Sales	Discontinued Product Line Impact	FX Impact	YTD 2006 Underlying Sales	
Heart Valve Therapy	\$ 260.8	\$ 252.9	\$ 7.9	3.1%	\$ (3.8)	\$ 257.0	\$ (6.3)	\$ 5.8	\$ 252.4	1.8%
Critical Care	188.3	170.7	17.6	10.3%	-	188.3	-	3.6	174.3	8.0%
Cardiac Surgery Systems	32.0	47.6	(15.6)	(32.8%)	(4.3)	27.7	(20.7)	0.6	27.5	0.6%
Vascular	42.5	37.3	5.2	13.9%	-	42.5	(1.3)	1.4	37.4	13.7%
Other Distributed Products	13.1	15.5	(2.4)	(15.5%)	-	13.1	(0.9)	(0.2)	14.4	(6.6%)
Total Sales	\$ 536.7	\$ 524.0	\$ 12.7	2.4%	\$ (8.1)	\$ 528.6	\$ (29.2)	\$ 11.2	\$ 506.0	4.5%

Sales by Region (QTD)	2Q 2007	2Q 2006	Change	GAAP Growth Rate
United States	\$ 120.5	\$ 122.6	\$ (2.1)	(1.7%)
Europe	78.5	69.1	9.4	13.6%
Japan	42.3	42.9	(0.6)	(1.4%)
Rest of World	31.3	32.7	(1.4)	(4.4%)
International	152.1	144.7	7.4	5.1%
Total	\$ 272.6	\$ 267.3	\$ 5.3	2.0%

Sales by Region (YTD)	YTD 2Q 2007	YTD 2Q 2006	Change	GAAP Growth Rate
United States	\$ 244.6	\$ 243.7	\$ 0.9	0.4%
Europe	152.4	133.8	18.6	13.9%
Japan	80.9	84.6	(3.7)	(4.4%)
Rest of World	58.8	61.9	(3.1)	(5.0%)
International	292.1	280.3	11.8	4.2%
Total	\$ 536.7	\$ 524.0	\$ 12.7	2.4%

* Numbers may not calculate due to rounding.